Chen Guan-Jong, Wu Fei, Pang Xin-Xin, Zhang Ai-Hua, Shi Jun-Bao, Lu Min, Tang Chao-Shu
Department of Nephrology, Peking University Third Hospital, Beijing, China.
Department of Pathology, Peking University Health Science Center, Beijing, China.
J Diabetes Investig. 2017 Jul;8(4):629. doi: 10.1111/jdi.12557. Epub 2016 Jul 26.
AIMS/INTRODUCTION: Urotensin II (UII) and autophagy have been considered as important components in the pathogenesis of diabetic nephropathy. The present study explores whether UII can regulate autophagy in the kidney, and its effect in diabetes.
Immunohistochemistry and western blot were carried out on the kidney tissues of diabetic UII receptor (UT) gene knockout mice, wild-type diabetic mice and normal control mice. For the in vitro experiment, HK-2 cells were treated with UII (10 mol/L) in the presence or absence of UT antagonist, SB-657510, (10 mol/L) or autophagy inducer, rapamycin (10 mol/L), for 12 h. Markers for autophagy (LC3-II, p62/SQSTM1) and extracellular matrix (fibronectin, collagen IV) were analyzed.
In diabetic UT knockout mice, expression of LC3-II is increased and p62 was reduced in comparison with that of the normal diabetic mice. Fibronectin and collagen IV were downregulated in diabetic UT knockout mice when compared with that of the normal diabetic mice. For the in vitro cell experiment, UII was shown to inhibit expression LC3-II and increase expression of p62 in comparison with that of the normal control. Treatment with SB-657510 can block UII-induced downregulation of LC3-II and upregulation of p62 while inhibiting UII-induced upregulation of fibronectin and collagen IV. Adding autophagy inducer, rapamycin, also inhibited UII-induced upregulation of fibronectin and collagen IV.
The present study is the first to show that UII can downregulate autophagy in the kidney while accompanying the increased production of extracellular matrix in early diabetes. Our in vitro study also showed that upregulation of autophagy can decrease UII-induced production of extracellular matrix in HK-2 cells.
目的/引言:尾加压素II(UII)和自噬被认为是糖尿病肾病发病机制中的重要组成部分。本研究探讨UII是否能调节肾脏中的自噬及其在糖尿病中的作用。
对糖尿病UII受体(UT)基因敲除小鼠、野生型糖尿病小鼠和正常对照小鼠的肾脏组织进行免疫组织化学和蛋白质印迹分析。在体外实验中,HK-2细胞在存在或不存在UT拮抗剂SB-657510(10 μmol/L)或自噬诱导剂雷帕霉素(10 μmol/L)的情况下,用UII(10 μmol/L)处理12小时。分析自噬标志物(LC3-II、p62/SQSTM1)和细胞外基质(纤连蛋白、IV型胶原)。
与正常糖尿病小鼠相比,糖尿病UT基因敲除小鼠中LC3-II的表达增加,p62减少。与正常糖尿病小鼠相比,糖尿病UT基因敲除小鼠中的纤连蛋白和IV型胶原下调。在体外细胞实验中,与正常对照相比,UII可抑制LC3-II的表达并增加p62的表达。用SB-657510处理可阻断UII诱导的LC3-II下调和p62上调,同时抑制UII诱导的纤连蛋白和IV型胶原上调。添加自噬诱导剂雷帕霉素也可抑制UII诱导的纤连蛋白和IV型胶原上调。
本研究首次表明,在糖尿病早期,UII可下调肾脏中的自噬,同时伴随着细胞外基质产生增加。我们的体外研究还表明,自噬上调可减少UII诱导的HK-2细胞中细胞外基质的产生。